Key Takeaways
- CRWV shares declined 3.4% to $83.53, touching an intraday bottom at $79.46, while trading volume fell 20% below typical levels
- Analysts maintain a Moderate Buy rating with a consensus price target of $135, with certain projections reaching $250
- Investor anxiety grows as Meta explores entering the AI cloud computing space, potentially challenging CoreWeave’s market position
- Company insiders have offloaded more than $3 billion in CRWV shares over the last 90 days, primarily through pre-scheduled tax withholding arrangements
- The company’s Q1 results disappointed on earnings, with EPS of -$1.40 versus expectations of -$1.17, despite revenue climbing 111.6% year-over-year to $2.08 billion
CoreWeave (CRWV) shares retreated 3.4% during Tuesday’s trading session, closing at $83.53 following an intraday decline that pushed the stock as low as $79.46. This represents a drop from the previous close of $86.46.
CoreWeave, Inc. Class A Common Stock, CRWV
Trading activity registered approximately 23 million shares, falling roughly 20% short of typical session volumes — indicating the decline wasn’t fueled by widespread panic among shareholders.
Year-to-date, the stock has gained 26%, though it remains down 41% over the trailing 12-month period and trades considerably below its 50-day moving average of $106.86.
The session’s weakness emerged amid mounting investor apprehension on two key issues: Meta’s potential expansion into AI computing services, and continuous insider stock dispositions.
A Bloomberg analysis highlighted that Meta is evaluating the possibility of offering AI computing infrastructure and raw computational resources to external clients — a strategic shift that would place it in direct rivalry with CoreWeave’s primary business operations.
Rosenblatt sustained its Buy recommendation with a $250 price objective, contending the Meta threat is exaggerated. Both Wolfe Research and Evercore ISI reaffirmed Outperform ratings with $150 targets.
Insider Transactions Draw Attention
Insider stock dispositions have attracted market scrutiny. Over the previous 90 days, company insiders have divested more than $3 billion in CRWV equity.
Most recently, General Counsel Kristen J. McVeety disposed of 22 shares valued at $1,889 on July 6, conducted through a Rule 10b5-1 trading plan established in May 2025.
Previously, insider Brian Venturo offloaded 76,912 shares on July 1 at an average price of $86.99, generating approximately $6.69 million in proceeds. This transaction reduced his holdings by 21%.
Insider Brannin McBee sold 56,707 shares on June 30 at $95.69 per share, totaling roughly $5.43 million — representing a 14.9% reduction in his ownership stake.
Both transactions were conducted via pre-established Rule 10b5-1 arrangements designed to satisfy tax liabilities on vesting equity compensation. While this represents standard practice, the magnitude has nonetheless prompted investor examination.
Recent Earnings Disappointment Lingers
CoreWeave’s most recent quarterly report, released May 7, failed to bolster investor confidence. The firm reported EPS of -$1.40, falling short of the -$1.17 analyst consensus by $0.23.
Revenue reached $2.08 billion, representing 111.6% year-over-year growth. While top-line expansion remains robust, profitability challenges persist — the company’s net margin stands at -25.57%.
Analyst projections forecast full-year EPS of -$4.57 on average.
Despite the earnings shortfall, multiple analysts maintain the recent selloff represents an overreaction. BNP Paribas holds the Street’s highest price objective at $192, while Cantor Fitzgerald projects $167. Wells Fargo elevated its target to $155 in May.
Among 35 analysts tracking the equity, 21 assign Buy ratings, 12 recommend Hold, and 2 rate it Sell.
The company carries a debt-to-equity ratio of 3.68, combined with a current ratio of merely 0.31 — a balance sheet profile that introduces considerable risk alongside the growth narrative.
CoreWeave’s market capitalization fluctuates between approximately $37–45 billion, varying by session. The company unveiled ARIA, an AI-powered research assistant, this week — though analysts view it as unlikely to significantly impact near-term performance.


